Objective To estimate the effect of denosumab compared with oral bisphosphonates on
reducing the risk of type 2 diabetes in adults with osteoporosis. Design Population based …

Importance Denosumab, a humanized monoclonal antibody against receptor activator of
nuclear factor κB ligand (RANKL), is a widely used antiresorptive medication for …

Purpose Diabetes and osteoporosis occur frequently in older adults and are both associated
with increased fracture risk. Denosumab treatment reduced new vertebral, nonvertebral, and …

Background Long-term safety and efficacy of osteoporosis treatment are important because
of the chronic nature of the disease. We aimed to assess the long-term safety and efficacy of …

ABSTRACT Type 2 diabetes (T2D) is associated with increased risk of fractures. However, it
is unclear whether current osteoporosis treatments reduce fractures in individuals with …

Comment 486 www. thelancet. com/diabetes-endocrinology Vol 5 July 2017 drug exposure.
Likewise, beneficial skeletal effects of the drug might not be maintained indefinitely …

The aim of this review is to compare the efficacy and safety of denosumab over other
treatments for osteoporosis. The results of this study suggest that the safety of denosumab …

Context It is uncertain which osteoporosis therapy is more effective: bisphosphonates or
denosumab. Objective To determine whether denosumab therapy increases bone mineral …

Osteoporosis and diabetes mellitus represent global health problems due to their high, and
increasing with aging, prevalence in the general population. Osteoporosis can be …

Context: Denosumab and zoledronic acid (ZOL) are parenteral treatments for patients with
osteoporosis. Objective: The objective of the study was to compare the effect of transitioning …